Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with a PD-1 Inhibitor in Patients with Non-Small Cell Lung Cancer

Why is the JASPER study being done?

This study will evaluate the following:

1) The combination of niraparib and a PD-1 inhibitor in people who have not received previous treatment and whose tumor expresses PD-L1. 

2) Niraparib as a potential treatment option for people who have squamous non–small cell lung cancer (sqNSCLC) and previously received clinical benefit from platinum chemotherapy (i.e. carboplatin, cisplatin, oxaliplatin).

For Groups 1 and 2 (NSCLC High or Low PD-L1 expressing): 

  • No known EGFR-sensitizing mutation and/or ROS-1 or ALK translocation
  • No prior chemotherapy

For Group 3 (Squamous NSCLC):

  • Disease progressed after both prior platinum-based chemotherapy and prior PD-1 or PD-L1 inhibitor treatment.

For Groups 1 and 2 (NSCLC High or Low PD-L1 expressing): 

  • For those with NSCLC - Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PDL2 agent.
  • For those with NSCLC - Active autoimmune disease that required treatment in the past 2 years.
  • History of interstitial lung disease, drug-related pneumonitis, or radiation pneumonitis requiring steroid treatment.

For Group 3 (Squamous NSCLC):

  • Platinum-treated patient who progressed while on or within less than 8 weeks from the last day of their last platinum chemotherapy treatment.
  • History of interstitial lung disease, drug-related pneumonitis, or radiation pneumonitis requiring steroid treatment.

 

HOW DO I KNOW IF THE JASPER STUDY IS RIGHT FOR ME?

The best next step is to contact the research site that would be the most convenient for you in order to discuss your medical history and whether the JASPER clinical trial would be a good fit.

To find sites in your area, contact: clinicaltrials@tesarobio.com or use the form above.

To find additional information on JASPER see: clinicaltrials.gov

Back to Search Results

To find a JASPER trial site near you, enter your email address and zip code below:

*
*

 

Additional Resources

About Immunotherapy 

About PARP Inhibitors

Clinical Trial FAQs

JASPER FAQ